Kaleido Capital Expenditure Trend from 2010 to 2021

KLDO -  USA Stock  

USD 5.83  0.38  6.97%

Kaleido Biosciences Capital Expenditure yearly trend continues to be quite stable with very little volatility. The value of Capital Expenditure is projected to decrease to -4,341,684. From the period between 2010 and 2021, Kaleido Biosciences, Capital Expenditure regression line of its data series had standard deviation of 1,187,748 and standard deviation of  1,187,748. Research and Development Expense is expected to rise to about 56 M this year, although the value of Consolidated Income will most likely fall to (88.1 M).

Search Historical Trends 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 2.2 M or Operating Expenses of 78.8 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.66 or Current Ratio of 4.08. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Capital Expenditure Breakdown

Showing smoothed Capital Expenditure of Kaleido Biosciences with missing and latest data points interpolated. A component of Net Cash Flow from Investing representing the net cash inflow (outflow) associated with the acquisition & disposal of long-lived; physical & intangible assets that are used in the normal conduct of business to produce goods and services and are not intended for resale. Includes cash inflows/outflows to pay for construction of self-constructed assets & software.Kaleido Biosciences' Capital Expenditure historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kaleido Biosciences' overall financial position and show how it may be relating to other accounts over time.
Capital Expenditure10 Years Trend
Decreasing
Slightly volatile
 Capital Expenditure 
Share
      Timeline 

Kaleido Capital Expenditure Regression Statistics

Arithmetic Mean(2,183,474)
Geometric Mean 1,941,713
Coefficient Of Variation(54.40)
Mean Deviation 1,036,632
Median(1,406,000)
Standard Deviation 1,187,748
Range 2,935,684
R-Value(0.84)
R-Squared 0.70
Significance 0.0006362
Slope(276,554)

Kaleido Capital Expenditure History

2018-3 M
2019-3.6 M
2020-4 M
2021-4.3 M

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's Capital Expenditure, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Capital Expenditure-4 M-4.3 M
Invested Capital15.3 M16.4 M
Invested Capital Average20.9 M20 M
Market Capitalization327.4 M310.8 M
Working Capital32.1 M43.6 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Kaleido Biosciences Investors Sentiment

The influence of Kaleido Biosciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kaleido. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KLDO

Kaleido Biosciences Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Kaleido Biosciences. What is your trading attitude regarding investing in Kaleido Biosciences? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.